The global health crisis of diabetes mellitus continues to worsen because of its increasing prevalence and insufficient treatment choices which lack effectiveness and affordability and individualized approaches. The diverse photosynthetic organism algae show promise as an underutilized source for developing new antidiabetic bioactive compounds in our current situation. The chapter investigates how multi-omics approaches including genomics, transcriptomics, proteomics, metabolomics, lipidomics, and emerging omics can speed up the development and discovery of algal therapeutics. The diabetes management mechanisms of algal metabolites including sulfated polysaccharide, omega-3 fatty acid, carotenoid and bioactive peptides involved in blood glucose regulation, insulin sensitivity and anti-inflammatory properties. Research on Chlorella, Nannochloropsis, Spirulina, and Haematococcus pluvialis species demonstrates how combined omics approaches can identify, validate and enhance these compounds. Structural biology and the System Model enable the function of the biosynthetic nerve pathway and the designation of the high-voltage target. Moreover, machine learning systems and machine learning transform facts integration and predictive models, allowing personalized and scalable creation of curative mixtures. Despite technical and infrastructure obstacles, the present part stresses the ability of multi-omics to revolutionize algal biotech and develop green, natural, and proficient solutions to diabetes management. Algal interventions could, in the long run, complement or even outperform traditional pharmaceutical approaches to treating metabolic disorders by convergent molecular biology, bioinformatics, and systems science.